tbuckley/cabot-search huggingface dataset:
Comparison of RNA interference silencing of PAX 2 expression in PC3 and Du145 prostate cancer cell lines.
Authors: Willietta Gibson, Ashley Green, Rebecca Bullard, Andre Eaddy, Carlton D. Donald
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

66 

Paired box genes are a family of transcriptional regulators that encode for transcription factors that help to guide expression of genes needed for normal development. Paired box genes have been implicated in acting as proto-oncogenes [1]. For example, Pax 2 is expressed in undifferentiated and highly mitotic tissues. The Pax 2 gene has been identified in renal cell carcinoma, Wilm’s tumor, and prostate cancer [2,3,4]. In this study, we are examining the role of Pax 2 in prostate cancer. Studies have shown that Pax 2 binds to the promoter region and may inhibit the expression of the tumor suppressor gene, P53. Previous studies have shown that Pax 2 may be required for cancer cell survival. Moreover, rapid induction of apoptosis is seen in bladder and ovarian cancer following RNA interference against Pax 2 expression [5]. Here we compare the effects of Pax 2 siRNA on cell viability in P53 null (PC3) versus P53 mutant (Du145) prostate cancer cells. The two cell lines were treated with a chemically synthesized siRNA of Pax2 for a 2, 4, and 6 day incubation time. Cellular proliferation and viability were measured in the siRNA treated cells using an in vitro MTT assay. Also, Pax 2 expression was assessed by Western Blot analysis. We established that the percent cell death of PC3 cells transfected with Pax 2 siRNA duplex was 3.7% at day 2 and increased to 37% by day 4 and further increased to approximately 63% by day 6. In contrast, Du145 cells transfected with Pax 2 siRNA duplex experienced approximately 18% cell death with no significant change at the four and six day incubation period. Western blot analysis confirmed lost of expression of Pax 2 as early as the fourth day. It appears that the P53 null PC3 cells treated with siRNA against Pax 2 experience more cell death than the mutated P53 Du145 cells treated with siRNA against Pax 2. This data suggest that Pax 2 may inhibit the function of P53 in PC3 cells which up on inhibition of Pax 2 expression, a P53- mediated pathway to cellular apoptosis may occur. Therefore, this study suggests that oncogenic activity of Pax 2 is mediated through the inhibition of P53- mediated apoptotic pathways.
Hepcidin Expression in Cultured Liver Cells Responds Differently to Iron Overloaded Sera Derived from Patients with Thalassemia and Hemochromatosis.
Authors: Orly Weizer, Konstantin Adamsky, Laura Breda, Ioav Cabantchik, Eliezer Rachmilewitz, William Breuer, Alon Harmelin, Carina Levin, Ariel Koren, Ninette Amariglio, Stefano Rivella, Gideon Rechavi
Journal: Blood (2004)
Analysis of Histone Deacetylase Inhibitor, FK228, Effect on Chronic Myelogenous Leukemia Cell Line.
Authors: Seiichi Okabe, Testuzo Tauchi, Akihiro Nakajima, Goro Sashida, Masahiki Sumi, Akihiko Gotoh, Kazuma Ohyashiki
Journal: Blood (2004)
Causes de mortalité après CPRE
Authors: F. Moryoussef
Journal: Endoscopy (2016)

Les taux de complications après CPRE oscillent entre 5 % et 12 %. Des modèles prédictifs de risque de survenue de ces complications semblent indispensables pour mieux sélectionner les patients. Ce travail avait donc pour premier objectif de valider un modèle britannique récemment décrit de prédiction du taux de mortalité sur une population suédoise à 30 jours 2 in exposant. Des données de mortalité au-delà de 30 jours étant peu disponibles, le deuxième objectif était d’étudier les causes de mortalité à moyen terme (3 – 12 mois) en mettant ainsi au point un autre modèle prédictif à partir du registre hospitalier suédois.
Awake ECMO on the move to lung transplantation: serial monitoring of physical condition
Authors: J. A. Hermens, S. A. Braithwaite, M. Platenkamp, P. R. Wijnandts, E. A. Van de Graaf, N. P. van der Kaaij, M. De Jong, G. Heijnen, J. Janssen, J. Kesecioglu, D. W. Donker
Journal: Intensive Care Medicine (2017)
Rituximab-induced viral infections in lymphoma patients
Authors: S. Aksoy, H. Harputluoglu, S. Kilickap, D. Sener Dede, O. Dizdar, K. Altundag, I. Barista
Journal: Journal of Clinical Oncology (2007)

18509 Background: Recently, a chimeric mouse human monoclonal antibody, rituximab, has been used successfully to treat cases of B-cell non-Hodgkin’s lymphoma (NHL) and some autoimmune diseases. However, several viral infections related to rituximab have been reported in literature, but not well characterized. Methods: To further investigate this topic, relevant English language studies were identified through Medline. For our search we used the generic name rituximab, and the key phrases virus/virus infection. The references from the identified articles were reviewed for additional sources. Results: There were 64 previously reported cases (26 male, 23 female, and 15 gender not reported) that had experienced serious viral infection after rituximab treatment. The median age of the cases was 61 years (range; 21–79 years). The median time period from the start of rituximab treatment to viral infection diagnosis was 5.0 months (range, 1–20). Most frequently experienced viral infections were hepatitis B virus infection in 25 (39.1%) cases, Cytomegalovirus infection in 15 (23.4%) cases, varicella zoster infection in 6 (9.4%) cases, and other viral infections in 18 (28.1%) cases. Thirteen (52.0%) of the patients with hepatitis B virus infection died due to hepatic failure. Thirty-nine of the cases had viral infections other than HBV and 13 of them died due to these specific infections. Conclusions: Viral infections after the rituximab treatment in lymphoma patients are important to recognize and treat early because of their association with substantial morbidity and mortality. In these case series, about 40% of these viral infections resulted in death. Close monitoring for viral infections in patients receiving rituximab is necessary. [Table: see text] No significant financial relationships to disclose.
Endoscopic septotomy: an effective approach for internal drainage of sleeve gastrectomy-associated collections
Authors: Srihari Mahadev, Vivek Kumbhari, Josemberg Campos, Manoel Galvao Neto, Mouen Khashab, Yamile Chavez, Marc Bessler, Tamas Gonda
Journal: Endoscopy (2017)

<b>Background and study aims</b> Staple-line leaks occur in 1 % – 7 % of patients who undergo sleeve gastrectomy, and can be challenging to treat. The success of endoscopic approaches decreases as leaks develop into chronic sinus tracts. Endoscopic septotomy has been used to facilitate healing of refractory leaks by incision and enlargement of the tract to allow direct communication with the gastric lumen and internal drainage. <b>Patients and methods</b> We reviewed the technique and outcomes among patients who underwent endoscopic septotomy at two centers for the management of sleeve gastrectomy-associated gastric fistulas and perigastric collections refractory to occlusive endoscopic therapies. <b>Results</b> Nine patients underwent endoscopic septotomy at a mean of 8.6 weeks after leak diagnosis, following failure of percutaneous and conventional endoscopic modalities. Perigastric collections ranged from 3 cm to 10 cm in size. The mean procedure time for endoscopic septotomy was 87.2 minutes. Multiple endoscopic septotomy procedures (mean 2.3, range 1 – 4) were required to achieve radiological resolution. The mean follow-up period was 21.2 weeks, and all nine patients achieved symptom resolution without the need for surgery. Bleeding at the time of endoscopic septotomy occurred in three patients, and was managed with endoscopic clips and did not require transfusion. No other adverse events or delayed complications were recorded. <b>Conclusions</b> Endoscopic septotomy appears to be a safe and effective technique for the management of sleeve gastrectomy-associated fistulae and collections, including those refractory to other endoscopic and percutaneous methods.
Quality of Life and Chronic Gvhd Severity According to the NIH Criteria: Results From the Chronic Gvhd Consortium
Authors: Joseph Pidala, Brenda Kurland, Shawn Chai, Navneet S. Majhail, Daniel J. Weisdorf, Corey Cutler, Madan Jagasia, Jeanne Palmer, Mukta Arora, Paul J. Martin, David Jacobsohn, Georgia B. Vogelsang, Steven Z. Pavletic, Stephanie J. Lee
Journal: Blood (2010)
RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC
Authors: V Selvarajan, M Osato, G S S Nah, J Yan, T-H Chung, D C-C Voon, Y Ito, M F Ham, M Salto-Tellez, N Shimizu, S-N Choo, S Fan, W-J Chng, S-B Ng
Journal: Leukemia (2017)
Patient interviews on hand-foot syndrome: Symptom assessment and impact on quality of life
Authors: M. Aklilu, R. T. Anderson, K. N. Keating, J. J. O’Leary
Journal: Journal of Clinical Oncology (2008)

20713 Background: With growth of oral antineoplastic agents, dose escalation and combination regimens, it is important to understand the scope of patient reported symptoms and health-related quality of life (HRQL) impacts. Sensitive, valid measures of HRQL are needed to detect treatment effects upon patient well-being and to compare treatment alternatives. We conducted in-depth face-to-face interviews of patients with hand-foot syndrome (HFS) to examine the breadth and range of HRQL issues for inclusion in future assessments, HFS affects up to 42% of patients treated with systemic chemotherapy and newer oral agents. Methods: In an IRB-approved study in two major cancer networks, two rounds of interviews were conducted, audio-taped and transcribed. Round one collected views on HRQL impact, life areas affected, and appraise items from existing health surveys relating to dermatological symptoms, activities of daily living (ADLs), psychological wellbeing and social functioning in 13 patients. Results were qualitatively tested in round two by asking 12 different patients to complete a prototype HRQL survey on HFS and participate in cognitive debriefing. Clinician and oncologist interviews were included to review face validity. Results: Study participants included 5 men and 7 women, ages 29 to 76, treated for cancer (colorectal, liver, kidney, breast, bile duct, and pancreatic) with anti-neoplastic agents including: capecitabine, sorafenib, sunitinib, taxanes, 5-FU and arsenic. Feedback was received on signs and symptoms of HFS and HRQL impact on ADLs, social life, work, psychological well-being and mood. Excellent face validity was found for the prototype assessment tool the HF-QoL. Future testing will assess reliability and responsiveness to change. Conclusions: Items were identified that are conceptually consistent with a range of patient reported experiences of HRQL impact from HFS, covering symptom distress, daily and physical functioning, social activities, psychological health, and sleep quality. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bayer Bayer Bayer
Genetic Disparities in Killer Cell Immunoglobulin-Like Receptors (KIR) and MHC Class I in Bone Marrow Failure Syndromes
Authors: P.K. Epling-Burnette, Jeffrey S. Painter, H.-S. Lee, Jong Park, Michael Clemente, Christine O’Keefe, Tie-Ying Wei, Sheng Wei, Jaroslaw Maciejewski, Thomas P. Loughran, Ron Paquette, Alan F. List, Julie Y Djeu
Journal: Blood (2008)
Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors
Authors: Marina Motta, Marco Chiarini, Marta Petullà, Claudia Ghidini, Marion Vaglio Tessitore, Viviana Giustini, Chiara Pagani, Antonella Anastasia, Samantha Ferrari, Alessandra Tucci, Luisa Imberti, Giuseppe Rossi
Journal: Blood (2015)
Clostridium Difficile Infections After Allogenic Hematopoietic Stem Cell Transplantation: Comparison of Cord Blood to Other Grafts
Authors: Kohei Hosokawa, Masanori Tsuji, Hideki Araoka, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Naofumi Matsuno, Naoyuki Uchida, Kazuhiro Masuoka, Atsushi Wake, Shigeyoshi Makino, Akiko Yoneyama, Akiyoshi Takami, Shinji Nakao, Shuichi Taniguchi
Journal: Blood (2011)
Hydrodynamic Isotonic Fluid Delivery Ameliorates Moderate-to-Severe Ischemia-Reperfusion Injury in Rat Kidneys
Authors: Jason A. Collett, Peter R. Corridon, Purvi Mehrotra, Alexander L. Kolb, George J. Rhodes, Caroline A. Miller, Bruce A. Molitoris, Janice G. Pennington, Ruben M. Sandoval, Simon J. Atkinson, Silvia B. Campos-Bilderback, David P. Basile, Robert L. Bacallao
Journal: Journal of the American Society of Nephrology (2017)

Highly aerobic organs like the kidney are innately susceptible to ischemia-reperfusion (I/R) injury, which can originate from sources including myocardial infarction, renal trauma, and transplant. Therapy is mainly supportive and depends on the cause(s) of damage. In the absence of hypervolemia, intravenous fluid delivery is frequently the first course of treatment but does not reverse established AKI. Evidence suggests that disrupting leukocyte adhesion may prevent the impairment of renal microvascular perfusion and the heightened inflammatory response that exacerbate ischemic renal injury. We investigated the therapeutic potential of hydrodynamic isotonic fluid delivery (HIFD) to the left renal vein 24 hours after inducing moderate-to-severe unilateral IRI in rats. HIFD significantly increased hydrostatic pressure within the renal vein. When conducted after established AKI, 24 hours after I/R injury, HIFD produced substantial and statistically significant decreases in serum creatinine levels compared with levels in animals given an equivalent volume of saline via peripheral infusion (P<0.05). Intravital confocal microscopy performed immediately after HIFD showed improved microvascular perfusion. Notably, HIFD also resulted in immediate enhancement of parenchymal labeling with the fluorescent dye Hoechst 33342. HIFD also associated with a significant reduction in the accumulation of renal leukocytes, including proinflammatory T cells. Additionally, HIFD significantly reduced peritubular capillary erythrocyte congestion and improved histologic scores of tubular injury 4 days after IRI. Taken together, these results indicate that HIFD performed after establishment of AKI rapidly restores microvascular perfusion and small molecule accessibility, with improvement in overall renal function.
Ifosfamide, carboplatin, and etoposide as front-line therapy in patients with Ewing sarcoma family tumors (EFT): A study of the Brazil/Uruguay Cooperative Group
Authors: A. L. Brunetto, L. A. Castillo, A. S. Petrilli, E. Boldrini, L. J. Gregianin, C. Costa, M. T. Almeida, K. Rosario, C. Rodriguez-Galindo, C. G. Castro, G. Dufort
Journal: Journal of Clinical Oncology (2009)

10547 Background: Chemotherapy (CT) with ifosfamide, carboplatin, and etoposide (ICE) is effective in refractory solid tumors. The aim of this trial was to determine the efficacy and safety of ICE as front line therapy for patients (pts) with newly-diagnosed EFT. Methods: Induction with 2 courses of ICE (ifosfamide 3g/m2/d ×3, carboplatin 450mg/m2 ×1, etoposide 150mg/m2/d ×3) plus 2 of VDC (vincristine 1,5mg/m2/d ×1, doxorubicin 60mg/m2/d ×1, cyclophosphamide 1,5g/m2/d ×1) was followed by surgery and/or radiotherapy. After induction, pts were allocated to low (LR) or high-risk (HR) according to LDH (&lt;or&gt;1,5×NL), site (pelvic/non-pelvic) and resection (complete/unresectable) or metastatic (mets). Postoperative CT included 10 alternating courses of IE and VDC for LR and 12 alternating courses of ICE and VDC for HR. Toxicity was assessed following 523, 648, 268 and 114 courses of ICE, VDC, IE and VC, respectively; 35 site visits were carried out for data quality control. Results: From 10/2003 to 10/2008, 150 of 159 enrolled pts were evaluable; median age 13y (0.2–29.3y). 44 pts were classified as LR and 101 as HR, 56 mts. Toxicity was mainly grade III-IV neutropenia, thrombocytopenia and febrile neutropenia, and was significantly higher following ICE. The 3y EFS and OS were 65% and 27% for localized pts and 80% and 43% for mets pts. 3y EFS for lung and non-lung mets were 40% and 19% (P=0.013). Multivariate analysis showed that mets disease was the only independent prognostic factor (P=0.006) for the entire group. However, when mts pts were analyzed separately, high LDH (P=0.01) and extra-lung site (P=0.016) had significant negative impact on survival. Conclusions: ICE regimen is safe and despite a high proportion of pts with advanced disease the survival are similar to larger series. Elevated LDH and the presence of extra-lung mets were significant negative prognostic factors in mets pts. Randomized trials to identify pts who may benefit from more intensive CT are warranted. No significant financial relationships to disclose.
AHSP (Alpha Hemoglobin Stabilizing Protein) Gene Expression during Normal and β-Thalassemic Erythroid Differentiation.
Authors: Luisa Ronzoni, Ilaria V. Libani, Giuliana Giribaldi, Franco Turrini, Daniela Rusconi, Chiara Refaldi, Maria Domenica Cappellini
Journal: Blood (2006)
A Phase I/II Trial Combining High-Dose Lenalidomide with Melphalan and Autologous Transplant for Multiple Myeloma: A Report of the Phase I Dose-Finding Study.
Authors: Attaya Suvannasankha, Sherif Farag, Rebecca Silbermann, Robin Obryant, Lisa l Wood, Abigail Huljak, Angie Secrest, Colin D. Crean, Rafat Abonour
Journal: Blood (2012)
Pharmacokinetics/Pharmacodynamic Relationship in Busulfan Conditioning Regimen: Results from a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation
Authors: Angelo Paci, Benedicte Neven, Vianney Poinsignon, Laura Faivre, Philippe Bourget, Sophie Broutin, Christelle Dufour, Jean-Hugues Dalle, Claire Galambrun, Bénédicte Devictor, Nathalie Bleyzac, Veronique Kemmel, Eva De Berranger, Virginie Gandemer, Jean Pierre Vannier, Jean Pierre Ranarivelo, Charlotte Jubert, Aurélie Pétain, Ellen Benhamou, Laurent Nguyen, Despina Moshous, Gilles Vassal
Journal: Blood (2014)
Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration
Authors: Gloria Alvarez-Sola, Iker Uriarte, M Ujue Latasa, Maite G Fernandez-Barrena, Raquel Urtasun, Maria Elizalde, Marina Barcena-Varela, Maddalen Jiménez, Haisul C Chang, Roberto Barbero, Victoria Catalán, Amaia Rodríguez, Gema Frühbeck, José M Gallego-Escuredo, Aleix Gavaldà-Navarro, Francesc Villarroya, Carlos M Rodriguez-Ortigosa, Fernando J Corrales, Jesus Prieto, Pedro Berraondo, Carmen Berasain, Matias A Avila
Journal: Gut (2017)

Fibroblast growth factor 15/19 (FGF15/19), an enterokine that regulates synthesis of hepatic bile acids (BA), has been proposed to influence fat metabolism. Without FGF15/19, mouse liver regeneration after partial hepatectomy (PH) is severely impaired. We studied the role of FGF15/19 in response to a high fat diet (HFD) and its regulation by saturated fatty acids. We developed a fusion molecule encompassing FGF19 and apolipoprotein A-I, termed Fibapo, and evaluated its pharmacological properties in fatty liver regeneration.Fgf15-/- mice were fed a HFD. Liver fat and the expression of fat metabolism and endoplasmic reticulum (ER) stress-related genes were measured. Influence of palmitic acid (PA) on FGF15/19 expression was determined in mice and in human liver cell lines. In vivo half-life and biological activity of Fibapo and FGF19 were compared. Hepatoprotective and proregenerative activities of Fibapo were evaluated in obese db/db mice undergoing PH.Hepatosteatosis and ER stress were exacerbated in HFD-fed Fgf15-/- mice. Hepatic expression of Pparγ2 was elevated in Fgf15-/- mice, being reversed by FGF19 treatment. PA induced FGF15/19 expression in mouse ileum and human liver cells, and FGF19 protected from PA-mediated ER stress and cytotoxicity. Fibapo reduced liver BA and lipid accumulation, inhibited ER stress and showed enhanced half-life. Fibapo provided increased db/db mice survival and improved regeneration upon PH.FGF15/19 is essential for hepatic metabolic adaptation to dietary fat being a physiological regulator of Pparγ2 expression. Perioperative administration of Fibapo improves fatty liver regeneration.
Changes in androgen receptor (AR) expression and its phosphorylated isoforms, in breast cancer (BC) patients treated with neoadjuvant letrozole.
Authors: Angel Guerrero, Rachel Ruoff, Joaquin Gavila, Susan Logan, Francisco Gozlabo, Miguel Angel Climent Duran, Vicente Guillem, Franco Muggia, Amparo Ruiz
Journal: Journal of Clinical Oncology (2014)

541 Background: Most of BC express the AR, and this is considered to be a good prognostic factor. However, AR signalling has also been implicated as a possible mechanism to aromatase inhibitors (AIs) resistance. Cell line models suggest a switch from estrogen to androgen-dependent growth as they become resistant to estrogen deprivation therapies. The goal of this study is to examine, in vivo, changes in AR and its phosphorylated sepecies during AI therapy, and to assess its potential role in outcome. Methods: Eighty four, consecutive, postmenopausal women, stage II-III primary estrogen receptor positive BC, were treated, in the same institution, with preoperatory letrozole between 2005 and 2012. Pre- and post-treatment BC tissues were examined by inmunohistochemestry for total AR and the phosphorylation of AR at serine 213 (pAR-S213) and serine 650 (pAR-S650). Results: Letrozole decreased the expression of pAR-S213, that was positive (H-score≥10) in 65% of pre-treatment samples vs 30% of post-treatment samples (p=0.001). No changes were observed for total AR (90% pre- vs 88% post-) and pAR-S650 (39% pre- vs 41% post-). Only pAR-S213 positivity after treatment was associated with a decreased rate of relapse free survival at 55 months (post-pAR-S213 negative: 90% vs post-pAR-S213 positive: 60%, p=0.0004), and remained significantly associated in a multivariate analysis including classic prognostic factors (PEPI score, Ki-67, ypTNM, ER). Conclusions: High expression of pAR-S213 after treatment with letrozole is associated with poor outcome, which suggest the possibility of therapeutic intervention with antagonist of AR activation.